

Comb *et al.* 09/535,364

LISTING OF CLAIMS

Claims 1-27. (cancelled)

Claim 28. (allowed) A motif-specific, context-independent antibody that specifically binds a recurring kinase consensus substrate motif or a protein-protein binding motif, said motif consisting of up to four invariant amino acids, at least one phosphorylated amino acid, and optionally, one or more variable/degenerate amino acid position(s), said antibody specifically binding said motif in a plurality of different peptides or proteins from an organism in which said motif recurs, wherein said antibody is not a site-specific antibody.

Claim 29. (allowed) (currently amended) The antibody of claim 28, wherein said kinase consensus substrate motif is selected from the group consisting of a MAPK consensus substrate motif[s] (PXS*P), CDK consensus substrate motifs (PXT*/S*PXR), PKA consensus substrate motifs (RXXXT*), Akt consensus substrate motifs (RXXXT*), and bulky ring directed kinase consensus substrate motifs ([F/X][T*/S*] or [S*/T*][F]), and wherein said protein protein binding motif is a 14-3-3-binding motif (RSXS*XP).

Claim 30. (allowed) The antibody of claim 28, wherein said antibody is monoclonal.

Claim 31. (allowed) The antibody of claim 28, wherein said antibody is polyclonal.

Claim 32. (allowed) The antibody of claim 28, wherein said antibody is produced by a method comprising the steps of:

- (a) constructing a combinatorial peptide library comprising (i) a fixed motif, wherein said fixed motif comprises said kinase consensus substrate motif or said protein-protein binding motif, and (ii) a plurality of degenerate amino acids surrounding said motif;
- (b) immunizing a host with said peptide library; and
- (c) isolating antisera from said host, and purifying said motif-specific, context-independent antibody from said antisera.

APPLICANTS: U.S.S.N.:

Comb *et al.* 09/535.364

Claim 33. (allowed) The antibody of claim 32, wherein said method further comprises the step of utilizing spleen cells from said host of step (b) to generate at least one monoclonal, motif-specific, context-independent antibody.

Claims 34-39. (cancelled)

Claim 40. (new) The antibody of claim 28, wherein said kinase consensus substrate motif is a CDK consensus substrate motif (PXT*/S*PXR).

Claim 41. (new) The antibody of claim 28, wherein said kinase consensus substrate motif is a PKA consensus substrate motif (RRXT*).

Claim 42. (new) The antibody of claim 28, wherein said kinase consensus substrate motif is an Akt consensus substrate motif (RXRXXT*).

Claim 43. (new) The antibody of claim 28, wherein said kinase consensus substrate motif is a bulky ring-directed kinase consensus substrate motif ([F/Y][T*/S*] or [S*/T*][F]).

Claim 44. (new) The antibody of claim 28, wherein said protein-protein binding motif is a 14-3-3 binding motif (RSXS*XP).

APPLICANTS:

Comb et al.

U.S.S.N.:

09/535,364

As noted above, the only amendment made to the presently-allowed claims (28-33) is to split out, into new dependent claims 40-44, the individual allowed species recited in the Markush group in allowed dependent claim 29. Upon entry of the present requested amendment, claims 28-33 and 40-44 have been allowed (and will issue as renumbered claims 1-11).

If the present papers are incomplete, the Issue group is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

James Gregory Cullem, Reg. No. 43,569

Intellectual Property Counsel

CELL SIGNALING TECHNOLOGY, INC.

Tel: (978) 867-2311

Dated: August 31, 2004